Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections

Houssein H Ayoub,†1 Laith J Abu-Raddad†2,3,4

ABSTRACT

Objective Direct-acting antivirals have opened an opportunity for controlling hepatitis C virus (HCV) infection in Pakistan, where 10% of the global infection burden is found. We aimed to evaluate the implications of five treatment programme scenarios for HCV treatment as prevention (HCV-TasP) in Pakistan.

Design An age-structured mathematical model was used to evaluate programme impact using epidemiological and programme indicators.

Setting Total Pakistan population.

Participants Total Pakistan HCV-infected population.

Interventions HCV treatment programme scenarios from 2018 up to 2030.

Results By 2030 across the five HCV-TasP scenarios, 0.6–7.3 million treatments were administered, treatment coverage reached between 3.7% and 98.7%, prevalence of chronic infection reached 2.4%–0.03%, incidence reduction ranged between 41% and 99%, programmatic reduction in incidence rate ranged between 7.2% and 98.5% and number of averted infections ranged between 126221 and 750547. Annual incidence rate reduction in the first decade of the programme was around 6%–18%. Number of treatments needed to prevent one new infection ranged between 4.7–9.8, at a drug cost of about US$900. Cost of the programme by 2030, in the most ambitious elimination scenario, reached US$708 million. Stipulated WHO target for 2030 cannot be sustained the programme including an elimination scenario.11

Conclusion HCV-TasP is a highly impactful and potent approach to control Pakistan’s HCV epidemic and achieve elimination by 2030.

INTRODUCTION

Viral hepatitis is the seventh leading cause of death globally.†1 Half of viral hepatitis deaths are attributed to hepatitis C virus (HCV).1-3 Pakistan is one of the most affected countries by this virus where HCV antibody (Ab) prevalence is estimated at 4.3% in 2017,4 with genotype 3 being most common in all provinces.5 Against this backdrop, HCV-TasP has undergone a revolution since 2013. Introduction of direct-acting antivirals (DAAs) furnished shorter and well-tolerated treatment regimens, with a success rate exceeding 90%.6 With the availability of DAAs, the WHO is calling for ambitious global targets for diagnosis, treatment and cure of viral hepatitis, signalling a major momentum towards HCV elimination by 2030.7

The Ministry of Health in Pakistan has launched its first National Hepatitis Strategic Framework following the WHO global targets.8,9 Importantly, the Government of Pakistan has made a commitment to provide diagnosis, treatment and care to patients infected by HCV free of cost in all provinces, through four regional Hepatitis Prevention and Control programmes.8 HCV patients will have access to DAA generics (eg, generic sofosbuvir and daclatasvir) with a cost of <US$100 per treatment course per person—one of the lowest costs globally.8,10

Following the recent proof-of-concept and approach of HCV treatment as prevention (TasP) in Egypt11 and our developed epidemiological model for the HCV epidemic in Pakistan,4 we aimed to assess the implications of HCV-TasP in Pakistan. We did so through different scenarios for scaling up and sustaining the programme including an elimination scenario by 2030, where elimination is defined as an incidence rate of <1 per 100000 person-year.11

Strengths and limitations of this Study

We used a nationally representative survey and a comprehensive database of systematically gathered HCV antibody prevalence data to fit the scale and the trend of the HCV epidemic in Pakistan.

We assessed the implications of HCV treatment as prevention in Pakistan using different plausible treatment baseline scenario up to an ambitious elimination scenario.

Future projections were generated by fitting the model to past and current data, but could be influenced by factors difficult to predict at present.
Mathematical model

Starting from our model for the Pakistan epidemic, we implemented an age-structured mathematical model as an adaptation and extension of earlier models and guidelines. Details of the model and parameterisation can be found in the supplementary material and in references.

Briefly, the model is a population-level compartmental mathematical model that describes HCV transmission in the whole population. The model stratified the population into categories according to level of HCV risk of exposure, status and stage of infection and age group. The model divided Pakistan’s population into seven age groups based on the available HCV Ab prevalence data, and accounted for heterogeneity in risk of exposure to the infection by incorporating five risk groups in the modelled population. Individuals from different risk and age groups mixed in the model according to mixing matrices that include both an assortative component and a proportionate component. The force of infection was defined in terms of the effective contact rates, HCV transmission probability per contact by HCV stage and mixing among the different age and risk groups.

Detailed descriptions of assumptions and model structure can be found in S1 Text and online supplementary table S1.

Data sources and model fitting

The model was parameterised using empirical data for HCV natural history and transmission (online supplementary text S2 and table S2). Demographic data were derived from the database of the Population Division of the United Nations Department of Economic and Social Affairs and Pakistan’s sixth Population and Housing Census-2017. Per our modelled epidemic in Pakistan, trends were estimated by fitting the model to a nationally representative and probability-based HCV Ab prevalence survey conducted in 2007–2008, and a comprehensive database of systematically gathered HCV Ab prevalence data. Detailed description of the model fitting to the data can be found in Ayoub et al.

Epidemiological and programme indicators

To inform public health response and following our approach for Egypt, we used epidemiological and programme indicators to assess the implications of Pakistan’s treatment programme. The definition of these measures can be found in online supplementary table S3.

The year 2010 was chosen as a reference year for several comparisons of outcome measures as suggested by WHO as a reference year, to have comparisons over complete two decades (2010, 2020 and 2030), and for consistency with the approach for Egypt. Treatment cost per person was assumed at US$100, mainly covering the cost of the generic DAAs. Furthermore, we applied an annual discount rate of 3% on future expenditures and on future savings (the latter being defined as infections averted).

Treatment programme scenarios

Informed by stakeholder discussions, programme data and experiences with similar scope programmes, the treatment programme was assumed to start in 2018 with a phase where the programme is being scaled up and that ends in 2020, followed by a phase where the programme is sustained from 2021 up to 2030, the elimination year. We assumed that there are no restrictions on treatment eligibility for any chronically infected person, regardless of liver disease stage or age. Success rate of treatment was assumed at 90%. We evaluated five HCV-TasP programme scenarios ranging from a conservative baseline scale-up scenario up to an ambitious elimination scenario (summarised in figure 1).
<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Number of treatments per year (2018–2020)</th>
<th>Number of treatments per year (2021–2030)</th>
<th>Number of treatments from 2018 up to 2020 (millions)</th>
<th>Number of treatments from 2018 up to 2030 (millions)</th>
<th>Incidence reduction by 2020 compared with 2010 (%)</th>
<th>Incidence reduction by 2030 compared with 2010 (%)</th>
<th>Number of HCV infections averted by 2020</th>
<th>Number of HCV infections averted by 2030</th>
<th>Number of treatments per infection averted by 2020</th>
<th>Number of treatments per infection averted by 2030</th>
<th>Cost per infection averted by 2020 (US$)</th>
<th>Cost per infection averted by 2030 (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline scale-up scenario</td>
<td>200 000</td>
<td>—</td>
<td>0.60</td>
<td>0.60</td>
<td>27%</td>
<td>41%</td>
<td>13 403</td>
<td>126 221</td>
<td>44.7</td>
<td>4.7</td>
<td>4 336</td>
<td>456</td>
</tr>
<tr>
<td>Scale-up and sustainability</td>
<td>200 000</td>
<td>200 000</td>
<td>0.60</td>
<td>2.60</td>
<td>27%</td>
<td>57%</td>
<td>13 403</td>
<td>301 259</td>
<td>44.7</td>
<td>8.6</td>
<td>4 336</td>
<td>834</td>
</tr>
<tr>
<td>scenario</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target 80% incidence reduction</td>
<td>200 000</td>
<td>490 000</td>
<td>0.60</td>
<td>5.50</td>
<td>27%</td>
<td>80%</td>
<td>13 403</td>
<td>568 869</td>
<td>44.7</td>
<td>9.7</td>
<td>4 336</td>
<td>941</td>
</tr>
<tr>
<td>scenario</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target 90% incidence reduction</td>
<td>200 000</td>
<td>599 000</td>
<td>0.60</td>
<td>6.60</td>
<td>27%</td>
<td>90%</td>
<td>13 403</td>
<td>675 640</td>
<td>44.7</td>
<td>9.8</td>
<td>4 336</td>
<td>951</td>
</tr>
<tr>
<td>scenario</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elimination scenario</td>
<td>200 000</td>
<td>670 000</td>
<td>0.60</td>
<td>7.30</td>
<td>27%</td>
<td>99%</td>
<td>13 403</td>
<td>750 547</td>
<td>44.7</td>
<td>9.7</td>
<td>4 336</td>
<td>941</td>
</tr>
</tbody>
</table>

HCV, hepatitis C virus.
Uncertainty analyses
To examine the range of uncertainty in the projected epidemic trajectories and treatment programme outcomes, we performed multivariable uncertainty analyses by implementing 1000 runs of the model. We assumed a 25% uncertainty around the parameters’ point estimates and applied Latin Hypercube sampling from a multidimensional distribution for the model’s structural parameters. Mean and associated 95% uncertainty interval were reported for HCV-TasP effectiveness and HCV incidence rate reduction (see online supplementary table S3 for definitions) by 2030 for each of the scenarios.

Patient and public involvement
Patients and/or public were not involved in this study.

RESULTS
Table 1 and figures 2-4 display the projected impact of the five programme scenarios. In absence of the programme, the epidemic was forecasted to decline slowly. While the prevalence of chronic infection and number of chronically infected individuals (and in need of treatment) were estimated at 3.2% and 6 665 900 in 2018, they were projected to decline to 3.0% and 6 655 300 by 2020, and 2.6% and 6 372 100 by 2030, respectively (figure 2).

Similarly, while HCV incidence rate per 100 000 person-year and number of new infections were estimated at 94 and 192 460 in 2018, they were projected to decline to 87 and 183 860 by 2020, and 62 and 150 360 by 2030, respectively (figure 3).

While total number of treatments administered by the end of the scale-up phase (in 2020) was 600 000 across the scenarios, by the end of the sustainability phase in 2030, it ranged between 0.6 million in the baseline scale-up scenario and 7.3 million in the elimination scenario. While incidence reduction was estimated at 27% by 2020 (with respect to 2010 incidence), it ranged between 41% and 99% by 2030. While prevalence of chronic infection declined to 2.8% by 2020, it ranged between 2.4% and 0.03% by 2030. While number of chronically infected individuals declined to 6 206 000 by 2020, it ranged between 5 868 600 and 8 604 000 by 2030.

Annual reduction in incidence rate in the baseline scale-up scenario was around 6% per year up to 2020 and declined thereafter, but in the remaining scenarios, it ranged between 6% and 15% per year up to 2025 and then increased thereafter. While incidence rate reduction due to the programme was estimated at 6.1% by 2020, it ranged between 7.2% and 98.5% by 2030. While number of averted infections was estimated at 13 403 by 2020, it ranged between 126 221 and 750 547 by 2030.
Figure 3  Impact of the five treatment programme scenarios on HCV incidence in Pakistan. (A) HCV incidence rate in the total population of Pakistan in the baseline scenario of no-treatment-intervention compared with the five treatment programme scenarios. (B) Annual number of new HCV infections in the total population of Pakistan in the baseline scenario of no-treatment-intervention compared with the five treatment programme scenarios. HCV, hepatitis C virus.

Figure 4  Incidence rate reduction in the scale-up phase and sustainability phase. (A) Incidence rate reduction in the total population of Pakistan strictly attributed to each of the five treatment programme scenarios. (B) Annual change in incidence rate in each of the five treatment programme scenarios.
Table 1 and figure 5 show key programme indicators for all programme scenarios. Treatment coverage in 2020 reached 6.2% across the scenarios, and by 2030, it ranged between 3.7% in the baseline scale-up scenario and 98.7% in the elimination scenario (figure 5A). Programme cost ranged between US$58.2 million and US$708.1 million by 2030. HCV-TasP effectiveness was around 45 by 2020, 18 by 2025 and 10 by 2030 across the various scenarios (table 1 and figure 5B). Cost per infection averted declined from US$4336 by 2020 to around US$900 by 2030 across the scenarios (table 1).

The multivariable uncertainty analyses supported the validity of our results and findings (online supplementary figure S1).

**DISCUSSION**

Pakistan is one of the most affected countries by HCV with about 10% of the global number of chronic infections, and 10% of the global HCV incidence. This study investigated and quantified the utility of HCV-TasP in this country and demonstrated that HCV-TasP is a strategic and indispensable approach to control the epidemic and to reach the WHO elimination target by 2030.

In context of availability of heavily discounted DAA generics in Pakistan, at a cost of <US$100 for a treatment course, there is a historic opportunity to control the HCV epidemic at a relatively low cost of <US$1 billion distributed over a decade and a half. This cost is minimal considering the future healthcare costs that are being averted, and other costs in terms of productivity, disability and premature mortality. With the time lag between infection and disease sequelae, lack of a meaningful and immediate scale-up of HCV-TasP will be translated into a growing disease burden of liver cirrhosis and cancer that Pakistan cannot afford. The strikingly persistent incidence adds up to an immense opportunity cost with failure to control the epidemic.

In all scenarios, HCV-TasP achieved substantial if not huge impact on incidence and chronic infection prevalence. By 2030, prevalence of chronic infection can reach 2.4%–0.03%, incidence reduction ranged between 41%–99% and incidence rate reduction due to the programme ranged between 7%–98%. The impact of the programme was also prompt to materialise with an annual incidence rate reduction of around 6% in the initial years. In the most ambitious elimination scenario, a total of 7.3 million individuals would have been treated and around 750,000 infections would have been averted, by 2030. For every nine DAA treatments, one infection would be averted by 2030, at a cost of about US$900. These key programme indicators illustrate how HCV-TasP is a cost-effective and potent intervention, and very likely a cost saving one against disease sequelae costs.

Pakistan has launched its first National Hepatitis Strategic Framework where free diagnosis, treatment, and care are being provided to infected people in different provinces through four Hepatitis Prevention and Control programmes. Pakistan has one of the least expensive
DAAs worldwide with the introduction of locally produced generics. Despite the affordability of DAAs, scale-up has been very modest with only 311,000 treated infections since DAAs introduction in 2013. Our results indicate that the WHO global target of 80% incidence reduction by 2030 cannot be attained unless the number of treatments per year reaches 490,000, and is kept at this level for a decade.

A recent modelling work also assessed the impact of HCV-TasP in Pakistan. The authors’ conclusions agreed with our conclusions that HCV-TasP is an effective and compelling intervention against HCV transmission. However, some of the results differed. They projected an increase in incidence and chronic infection prevalence in absence of treatment, but our analyses projected a slow decline. This difference arose from differences in the model input data. They used data of the national (2007–2008) survey, surveys among people who inject drug (PWID) and blood donor testing. Meanwhile, we used data of the national (2007–2008) survey and an extensive database of HCV Ab prevalence data generated through a systematic review. Their analyses considered also different treatment programme scenarios than ours. With the differences in epidemic projections, they estimated substantially higher number of treatments to reach the WHO global target by 2030 than we did.

The relevance and feasibility of scaling up Pakistan’s programme can be seen in Egypt’s successful experience of scaling up the treatment programme. With the rapidly declining incidence and two million less prevalent chronic infections in Egypt, Pakistan’s programme can be even more impactful. By reaching elimination by 2030, the number of averted infections will be more than 50% higher than that in Egypt and more cost effective—10 treatments are needed to avert one infection in Pakistan compared with 12 in Egypt.

Despite the opportunity for scaling up HCV-TasP, the programme may soon encounter a major hurdle: identifying chronically infected individuals. The programme will not be able to yield its potential without active case finding. Our understanding of HCV epidemiology in Pakistan remains insufficient to develop cost-effective screening strategies, unlike Egypt where the epidemic is thoroughly investigated. While an understanding of epidemic drivers is being developed, screening can initially target >40 birth cohorts, who are more affected, and provinces with higher prevalence. With evidence for a major role for healthcare exposures and injecting drug use, targeting screening to these settings could be effective. Screening can also be scaled up using awareness campaigns and accessible mobile and fixed testing units, and should be targeting geographic localities with higher HCV prevalence.

A recent study provided a conceptual map for a testing programme with focus on Pakistan and Egypt. The study showed that testing strategies can be much more efficient through population prioritisation by risk of exposure. For example, testing efficiency was highest by targeting, respectively, populations with liver conditions, PWID, populations with high-risk healthcare exposures and special clinical populations, where only 2–4 tests would be needed to identify a chronic infection, followed by populations at intermediate risk, and eventually general populations.

Current evidence suggests that HCV transmission in Pakistan is mostly driven by healthcare-related exposures, such as poor sterilisation of medical equipment, intravenous infusions and therapeutic injections. Although Pakistan has made strides to improve blood screening, safe injection and other infection control measures, and has been increasing HCV treatment coverage, commitment to prevention in the different segments of the healthcare system is warranted for this country to reduce further HCV incidence and to accomplish the HCV elimination target by 2030.

As for limitations of the present analyses, we did not include previous treatments (prior to 2018), but treatment coverage has been limited up to today. We assumed any chronically infected individual can be treated, but treatment may not be indicated for all. The cost per infection averted included only the cost of the drug and its direct implementation, but it did not include the cost of screening/testing to identify the chronically infected individuals. Future work needs to explore the cost effectiveness of combined HCV testing and treatment programmes. Most biological parameters used in the model were found in the literature based on studies including PWID, which may affect their generalisability. Future incidence can be uncertain as it depends on unpredictable factors, such as scale-up of other interventions. We used a complex mathematical model to describe HCV transmission in the population, but predictions may be contingent on type of model and its input data. To account (partially) for limitations, we performed multivariable uncertainty analyses, and these affirmed our results (online supplementary figure S1).

In conclusion, we assessed the impact of HCV-TasP in Pakistan through different programme scenarios. Projected programme outcomes demonstrated HCV-TasP as a strategic and indispensable approach to control the epidemic and to achieve elimination by 2030. Pakistan has a golden opportunity to avert 750,000 new infections, and to eliminate much of HCV chronic infections by expanding its treatment programme.

**Contributors** HHA designed the mathematical model, conducted the analyses and wrote the first draft of the paper. LJA-R conceived and led the design of the study and model, analyses and drafting of the article. All authors have read and approved the final manuscript.

**Funding** This publication was made possible by NPRP grant number 9-040-3-008 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors. The authors are also grateful for support provided by the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar.

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.